Stereotaxis (NYSEAMERICAN:STXS) Stock Price Down 1.8% – What’s Next?

Posted by Stanley Muller on Oct 10th, 2026

Stereotaxis Inc. (NYSEAMERICAN:STXS – Get Free Report) dropped 1.8% on Thursday. The stock traded as low as $1.09 and last traded at $1.11. Approximately 560,344 shares traded hands during trading, an increase of 5% from the average daily volume of 534,283 shares. The stock had previously closed at $1.13.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on STXS shares. TD Cowen decreased their price target on shares of Stereotaxis from $5.00 to $3.00 and set a “buy” rating on the stock in a research note on Wednesday, August 12th. Citizens Jmp reduced their target price on shares of Stereotaxis from $4.00 to $3.00 and set a “market outperform” rating on the stock in a report on Thursday, August 27th. Finally, Citigroup restated an “outperform” rating on shares of Stereotaxis in a research report on Thursday, August 27th. Five equities research analysts have rated the stock with a Buy rating. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $3.50.

Check Out Our Latest Research Report on STXS

Stereotaxis Price Performance

The stock has a market cap of $111.22 million, a PE ratio of -4.62 and a beta of 1.37. The firm has a 50 day moving average price of $1.34 and a 200 day moving average price of $1.64.

Stereotaxis (NYSEAMERICAN:STXS – Get Free Report) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.05) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.05). The company had revenue of $7.67 million for the quarter, compared to analyst estimates of $8.35 million. Stereotaxis had a negative net margin of 74.24% and a negative return on equity of 130.84%. Equities analysts forecast that Stereotaxis Inc. will post -0.22 earnings per share for the current year.

Institutional Trading of Stereotaxis

Several institutional investors and hedge funds have recently bought and sold shares of the business. Bank of New York Mellon Corp acquired a new position in shares of Stereotaxis in the second quarter worth about $364,000. Sei Investments Co. raised its holdings in shares of Stereotaxis by 108.9% during the first quarter. Sei Investments Co. now owns 518,884 shares of the company’s stock valued at $955,000 after acquiring an additional 270,443 shares during the last quarter. Finally, Sequoia Financial Advisors LLC acquired a new position in shares of Stereotaxis during the first quarter valued at approximately $700,000. 45.35% of the stock is currently owned by institutional investors and hedge funds.

About Stereotaxis

(Get Free Report)

Stereotaxis, Inc develops robotic systems and related technologies for minimally invasive cardiovascular procedures. Its primary focus is the treatment of cardiac arrhythmias, including atrial fibrillation and ventricular tachycardia, through catheter-based electrophysiology procedures.

The company’s product portfolio includes robotic magnetic navigation systems, such as the Genesis and Niobe platforms, which use computer-controlled magnets to guide specialized catheters through the heart.